Tagged with access,

Bulgaria Nikolaos Xydias, general manager at GSK Bulgaria, explains the commitment of GSK to cutting-edge medicines and vaccines targeting respiratory diseases and HIV and highlights the reasons why pharmaceutical multinationals should put Bulgaria on their business map. This is your first time as a country manager. How did you prepare yourself…

Brazil Luciano Finardi, general manager of Celgene Brazil, describes the unrivalled commitment of the company to Brazilian patients and documents the remarkable dedication of Celgene to registering its flagship product in Brazil, as well as the company’s willingness to cope with the country’s unpredictability while establishing its operation in Brazil. Celgene…

Bulgaria Metodija Chadikovski, general manager at Roche Bulgaria, explains the importance of conducting high quality diagnostics to successfully target the right drug to the right patient as well as the affiliate’s commitment to developing the solutions that Bulgarian patients will need next. Could you please introduce yourself as well as your…

Bulgaria Krassimira Chemishanska, country director at Amgen Bulgaria, showcases the role of innovative players in the country, the importance of moving towards a value-based assessment system, and how Amgen has performed since its entrance to the Bulgarian market back in 2009. You opened the Bulgarian affiliate back in 2009. How challenging…

Bulgaria Urszula Orzel, general manager at MSD Bulgaria, explains how the affiliate has become one of the fastest growing players in the country and emphasizes that pharmaceutical companies are not merely manufacturers of drugs, but should also be socially committed. This is your first time as a country manager. How did…

Tunisia Walid Lakhdar, country business unit head for Tunisia and Libya at Pfizer, stresses the company’s ongoing dedication to patients in Tunisia. This was illustrated by the significant investments Pfizer has made in Tunisia after the revolution and still continues to make. Lakhdar talks about Pfizer’s successful partnerships in the country…

Austria Dr. Wolfgang Harrer, regional manager of Chiesi Central and Eastern Europe (CEE), discusses the challenges of managing the region’s diverse cultural differences and the importance of CEE within global operations. Furthermore, he points out the factors influencing the influx of innovative drugs into Austria, especially in rare diseases, and highlights…

India Bhupendra Singh, chairman of the Indian National Pharmaceutical Pricing Authority (NPPA), provides an overview of the current mechanisms governing the pharmaceutical and life sciences industry in India, highlighting the challenges of the current pricing climate, and the ultimate goal of providing affordable and accessible medicines to the nation’s roughly 1.3…

Bulgaria Stanimir Hasurdjiev explains the key role of the National Patients’ Organization (NPO) in Bulgaria and discusses the main areas that he is working on to ensure that patients are heard and can benefit from the best treatments and care available at a reasonable price.    You are working in different…

Austria Rudolf Wessely, CEO and founder of Gynial, the Austrian leader in oral contraceptives, elaborates on the company’s incredibly fast market penetration since 2007 and explains his expertise in the contraceptive field. Furthermore, he discusses the importance of open communication with gynaecologists and Gynial’s unique product philosophy as well as the…

ARM Annie Hubert, Senior Director, EU Section & Public Policy for the Alliance for Regenerative Medicine (ARM) describes some of the issues that companies in the advanced therapies field are facing in terms of market access and stakeholder education in Europe, as well as some of the key breakthroughs that European…

Canada Michael Tremblay, president and CEO of Astellas Pharma Canada, Inc., draws upon his four decades of experience within the Canadian pharmaceutical industry to discuss his thoughts on the need for Canada to move away from a ‘silo-ed’ approach to healthcare spending, the value that Astellas has been bringing to patients…